Overview

A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer

Status:
Withdrawn

Trial end date:
2018-01-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the safety of the study drug ramucirumab in combination with weekly docetaxel in participants with stage IV non-small cell lung cancer (NSCLC) following disease progression after prior platinum-based chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Docetaxel
Ramucirumab